200 related articles for article (PubMed ID: 29079283)
21. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.
Kim YR; Kim SJ; Cheong JW; Yang DH; Lee H; Eom HS; Sung YO; Kim HJ; Kang HJ; Lee WS; Park Y; Yang WI; Min YH; Kim JS
Ann Hematol; 2016 Sep; 95(9):1491-501. PubMed ID: 27324387
[TBL] [Abstract][Full Text] [Related]
22. Consolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphoma.
Nie M; Bi XW; Zhang WW; Sun P; Xia Y; Liu PP; Huang HQ; Jiang WQ; Li ZM
Sci Rep; 2016 Apr; 6():23996. PubMed ID: 27041507
[TBL] [Abstract][Full Text] [Related]
23. Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma.
Kim Y; Kim SJ; Cheong JW; Cho H; Chung H; Lee JY; Jang JE; Min YH; Kim JS
Hematol Oncol; 2017 Dec; 35(4):465-471. PubMed ID: 27440113
[TBL] [Abstract][Full Text] [Related]
24. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U
Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029
[TBL] [Abstract][Full Text] [Related]
25. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study.
Wang T; Xu L; Gao L; Tang G; Chen L; Chen J; Wang Y; Fu W; Yue W; Ye M; Yu J; Yu X; Feng D; Zhang A; Yang J
Hematol Oncol; 2022 Oct; 40(4):637-644. PubMed ID: 35141937
[TBL] [Abstract][Full Text] [Related]
26. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.
Nademanee A; Forman SJ
Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.
Nagle SJ; Woo K; Schuster SJ; Nasta SD; Stadtmauer E; Mick R; Svoboda J
Am J Hematol; 2013 Oct; 88(10):890-4. PubMed ID: 23813874
[TBL] [Abstract][Full Text] [Related]
28. Favorable Outcomes with R-CHOP Induction and Consolidative Autologous Stem Cell Transplantation for Double-Hit Lymphoma.
Puckrin R; Sterrett R; Shafey M; Chua N; Stewart D
Transplant Cell Ther; 2022 Nov; 28(11):762.e1-762.e4. PubMed ID: 36058549
[TBL] [Abstract][Full Text] [Related]
29. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study.
Chihara D; Izutsu K; Kondo E; Sakai R; Mizuta S; Yokoyama K; Kaneko H; Kato K; Hasegawa Y; Chou T; Sugahara H; Henzan H; Sakamaki H; Suzuki R; Suzumiya J
Biol Blood Marrow Transplant; 2014 May; 20(5):684-9. PubMed ID: 24492141
[TBL] [Abstract][Full Text] [Related]
30. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
31. Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.
Riedell PA; Bishop MR
Bone Marrow Transplant; 2018 Jan; 53(1):11-21. PubMed ID: 28967896
[TBL] [Abstract][Full Text] [Related]
32. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
[TBL] [Abstract][Full Text] [Related]
33. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
[TBL] [Abstract][Full Text] [Related]
34. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
Kewalramani T; Zelenetz AD; Teruya-Feldstein J; Hamlin P; Yahalom J; Horwitz S; Nimer SD; Moskowitz CH
Br J Haematol; 2006 Jul; 134(2):202-7. PubMed ID: 16759221
[TBL] [Abstract][Full Text] [Related]
35. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
Wagner-Johnston ND; Goy A; Rodriguez MA; Ehmann WC; Hamlin PA; Radford J; Thieblemont C; Suh C; Sweetenham J; Huang Y; Sullivan ST; Vandendries ER; Gisselbrecht C
Leuk Lymphoma; 2015; 56(10):2863-9. PubMed ID: 25707288
[TBL] [Abstract][Full Text] [Related]
36. Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
Shin HJ; Lee WS; Lee HS; Kim H; Lee GW; Song MK; Kim JS; Yhim HY; Chung JS
Leuk Lymphoma; 2014 Nov; 55(11):2490-6. PubMed ID: 24432893
[TBL] [Abstract][Full Text] [Related]
37. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma.
Kuruvilla J; Pintilie M; Tsang R; Nagy T; Keating A; Crump M
Leuk Lymphoma; 2008 Jul; 49(7):1329-36. PubMed ID: 18604722
[TBL] [Abstract][Full Text] [Related]
38. Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
Campbell BA; Brown R; Lambertini A; Hofman MS; Bressel M; Seymour JF; Wirth A; MacManus M; Dickinson M
Br J Haematol; 2023 May; 201(3):502-509. PubMed ID: 37015002
[TBL] [Abstract][Full Text] [Related]
39. Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
Patil S; Spencer A; Schwarer A; Avery S; Ritchie D; Opat S; Wei A; McLean C
Leuk Lymphoma; 2009 Dec; 50(12):1964-8. PubMed ID: 19860614
[TBL] [Abstract][Full Text] [Related]
40. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
Merryman RW; Redd RA; Taranto E; Ahmed G; Jeter E; McHugh KM; Brown JR; Crombie JL; Davids MS; Fisher DC; Freedman AS; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Jacene H; Park H; Dahi PB; Nieto Y; Joyce RM; Chen YB; Shipp MA; Herrera AF; Armand P
Blood Adv; 2023 Sep; 7(17):4748-4759. PubMed ID: 36399518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
